Status:
UNKNOWN
Treatment of Non-severe Covid-19 Outpatients With Xagrotin, Phase 3
Lead Sponsor:
Biomad AS
Conditions:
Sars-cov-2
Eligibility:
All Genders
18-99 years
Phase:
PHASE3
Brief Summary
This is an interventional, multi-center, randomized study. Adults with confirmed covid-19 disease not more than 10 days before enrollment date will be recruited (n=1000). Patients in same condition wh...
Detailed Description
An interventional, multi-center, randomized study that will performe in an outpatient setting (n=1000). Adults with confirmed covid-19 disease not more than 10 days before enrollment date will be recr...
Eligibility Criteria
Inclusion
- Age 18 or higher
- Newly diagnosed (no longer than 10 days)
- PCR or clinically confirmed Covid-19
Exclusion
- Coronavirus patients admitted to medical centers for hospitalization and receive medical treatment and necessary care in medical centers
Key Trial Info
Start Date :
June 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 7 2022
Estimated Enrollment :
3000 Patients enrolled
Trial Details
Trial ID
NCT05222425
Start Date
June 1 2022
End Date
December 7 2022
Last Update
March 17 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Directorate of health of Sulaimani, Iraq -KRG
Sulaymaniyah, Iraq